PMID- 27468867 OWN - NLM STAT- MEDLINE DCOM- 20170302 LR - 20220321 IS - 1699-3055 (Electronic) IS - 1699-048X (Linking) VI - 19 IP - 3 DP - 2017 Mar TI - Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. PG - 332-340 LID - 10.1007/s12094-016-1534-9 [doi] AB - PURPOSE: Changes in EGFR profiles of non small cell lung cancer (NSCLC) patients correlates to clinical outcome. Extracting quality tumor tissue remains a challenge for molecular profiling. Our study aims to ascertain the clinical relevance of urinary cell free DNA as an alternative tumor material source. METHODS: 150 patients with activating EGFR mutation and received EGFR-TKIs were recruited to participate in the serial monitoring study. Matched primary tumor samples were taken together with blood and urine specimens before the initiation of TKIs. The EGFR mutation testing was performed and quantified using ddPCR. For serial time point measurements, urine and blood samples were extracted at 1-month intervals for duration of 9 months. RESULTS: Urinary ctDNA yielded a close agreement of 88 % on EGFR mutation status when compared to primary tissue at baseline. Almost all samples detected via urine specimens were uncovered in plasma samples. Analysis of urinary cell free DNA at different time points showed a strong correlation to treatment efficacy. Interestingly, a secondary EGFR mutation T790M was detected for 53 % of the patients during monitoring. The results were corroborated with the plasma ctDNA analysis. The T790M+ group had a reduced median survival when compared to the wildtype group. CONCLUSION: Urinary cell free DNA may be a potential alternative to conventional primary tissue based EGFR mutation testing. Our findings showed that the assay sensitivity was comparable to results from blood plasma. Urinary samples being noninvasive and readily available have clinical utility for monitoring of EGFR TKI treatment. FAU - Chen, S AU - Chen S AD - Department of Academic Affairs, Hubei University of Medicine, Shiyan, 442000, Hubei, China. FAU - Zhao, J AU - Zhao J AD - Department of Oncology, Xiangyang Central Hospital (The Affiliated Hospital of Hubei College of Arts and Science), Xiangyang, 441021, Hubei, China. FAU - Cui, L AU - Cui L AD - Department of Nephrology, Xiangyang Central Hospital (The Affiliated Hospital of Hubei College of Arts and Science), Xiangyang, 441021, Hubei, China. FAU - Liu, Y AU - Liu Y AD - Department of Oncology, Xiangyang Central Hospital (The Affiliated Hospital of Hubei College of Arts and Science), Xiangyang, 441021, Hubei, China. yyliuXYcentral@hotmail.com. LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20160728 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 RN - 0 (Biomarkers, Tumor) RN - 0 (DNA, Neoplasm) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Adenocarcinoma/drug therapy/pathology/urine MH - Biomarkers, Tumor/*urine MH - Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/*urine MH - Case-Control Studies MH - DNA, Neoplasm/genetics/*urine MH - ErbB Receptors/*genetics/urine MH - Female MH - Follow-Up Studies MH - Humans MH - Lung Neoplasms/drug therapy/pathology/urine MH - Male MH - Middle Aged MH - Mutation/*genetics MH - Neoplasm Staging MH - Neoplastic Cells, Circulating/drug effects/metabolism MH - Polymerase Chain Reaction MH - Prognosis MH - Protein Kinase Inhibitors/*therapeutic use MH - Survival Rate OTO - NOTNLM OT - Cell free DNA OT - Drug resistance OT - EGFR mutations OT - Liquid biopsy OT - NSCLC OT - TKI treatment EDAT- 2016/07/30 06:00 MHDA- 2017/03/03 06:00 CRDT- 2016/07/30 06:00 PHST- 2016/06/29 00:00 [received] PHST- 2016/07/20 00:00 [accepted] PHST- 2016/07/30 06:00 [pubmed] PHST- 2017/03/03 06:00 [medline] PHST- 2016/07/30 06:00 [entrez] AID - 10.1007/s12094-016-1534-9 [pii] AID - 10.1007/s12094-016-1534-9 [doi] PST - ppublish SO - Clin Transl Oncol. 2017 Mar;19(3):332-340. doi: 10.1007/s12094-016-1534-9. Epub 2016 Jul 28.